Portola Pharmaceuticals, Inc. (PTLA)


NasdaqGS - NasdaqGS Real Time Price. Currency in USD
23.20-0.52 (-2.19%)
At close: 4:00 PM EDT
People also watch:
OPHTPTCTTSROCLVSCEMP
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Open23.57
Prev Close23.72
Bid0.00 x
Ask38.80 x 200
Day's Range23.18 - 23.90
52wk Range18.20 - 52.89
1y Target EstN/A
Market Cap1.31B
P/E Ratio (ttm)-5.21
Beta1.48
Volume527,723
Avg Vol (3m)1,121,814
Dividend & YieldN/A (N/A)
Earnings DateN/A
Trade prices are not sourced from all markets
  • Forget Sarepta Therapeutics, Here Are 3 Other Biotech Stocks to Buy
    Motley Fool6 days ago

    Forget Sarepta Therapeutics, Here Are 3 Other Biotech Stocks to Buy

    Upcoming FDA decisions could lead to Portola Pharmaceuticals, Puma Biotech, and Tesaro Inc. outperforming Sarepta Therapeutics.

  • Capital Cube6 days ago

    Portola Pharmaceuticals, Inc. – Value Analysis (NASDAQ:PTLA) : September 20, 2016

    Categories: Fundamental Analysis Yahoo Finance Click here to see latest analysis Capitalcube gives Portola Pharmaceuticals, Inc. a score of 29. Our analysis is based on comparing Portola Pharmaceuticals, Inc. with the following peers – Johnson & Johnson, Pfizer Inc., Sanofi Sponsored ADR, Biogen Inc., Bristol-Myers Squibb Company and Tobira Therapeutics, Inc. (JNJ-US, PFE-US, SNY-US, BIIB-US, BMY-US and TBRA-US). Investment Outlook ... Read more (Read more...)

  • Forbes7 days ago

    After Losing Medivation, Who Is Gilead Going After Next?

    Gilead Sciences has been consistently pressured by analysts to make an acquisition over the past 18 months. The company has been incredibly frugal, stockpiling cash, and avoiding overpaying in an acquisition just to make the analysts happy. They made a bid to purchase Medivation, but lost out to Pfizer. Todd Hagopian says that GILD’s performance the last 15 months (down 34% from it’s high), and it’s huge stockpile of cash (recently bolstered through a $5 billion debt offering), make it unlikely the company will be able to hold off from making a strategic acquisition much longer.